Risk of hospitalization for upper gastrointestinal tract bleeding

Journal of Clinical Epidemiology

Volumn 57, Issue 1, 2004, Pages 103-110

  Gallerani, M ^a   Simonato, M ^a   Manfredini, R ^a   Volpato, S ^a   Vigna, G B ^a   Fellin, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Clinical characteristics; Hospitalization; UGIB; Upper gastrointestinal tract bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ETACRYNIC ACID; IRON; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROPRANOLOL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DUODENUM BLEEDING; ESOPHAGUS HEMORRHAGE; EVALUATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SEX; SIDE EFFECT; SMOKING AND SMOKING RELATED PHENOMENA; STATISTICAL ANALYSIS; STOMACH HEMORRHAGE; UPPER GASTROINTESTINAL BLEEDING;

EID: 1342324128     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(03)00255-5     Document Type: Article

References (57)

1. Longstreth G.F. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: A population-based study. Am J Gastroenterol. 90:1995;206-210.
2. Rockall T.A., Logan R.F., Devlin H.B., Northfield T.C. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ. 311:1995;222-226.
3. Masson J., Bramley P.N., Herd K., McKnight G.M., Park K., Brunt P.W., McKinlay A.W., Sinclair T.S., Mowat N.A. Upper gastrointestinal bleeding in an open-access dedicated unit. J R Coll Physicians Lond. 30:1996;436-442.
4. Paspatis G.A., Martella E., Kapsoritakis A., Leontithis C., Papanikolaou N., Chloverakis G.J., Koiroumalis E. An epidemiological study of acute upper gastrointestinal bleeding in Crete, Greece. Eur J Gastroenterol Hepatol. 12:2000;1215-1220.
5. Phang T.S., Vornik V., Stubbs R. Risk assessment in upper gastrointestinal haemorrhage: implications for resource utilisation. N Z Med J. 113:2000;331-333.
6. Yavorski R.T., Wong R.K., Maydonovitch C., Battin L.S., Furnia A., Amundson D.E. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. Am J Gastroenterol. 90:1995;568-573.
7. Corley D.A., Stefan A.M., Wolf M., Cook E.F., Lee T.H. Early indicators of prognosis in upper gastrointestinal hemorrhage. Am J Gastroenterol. 93:1998;336-340.
8. Shafi M.A., Flescher D.E. Risk factors of acute ulcer bleeding. Hepatogastroenterology. 46:1999;727-731.
9. Farrell J.J., Friedman L.S. Gastrointestinal bleeding in the elderly. Gastroenterol Clin North Am. 30:2001;377-407.
10. Fiaccadori E., Maggiore U., Clima B., Melfa L., Rotelli C., Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 59:2001;1510-1519.
11. Hawkey C.J. Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ. 300:1990;278-284.
12. Bollini P., Garcia Rodriguez L.A., Pérez Gutthann S., Walker A.M. The impact of research quality and study design on epidemiologic estimates of the effect of NSAIDs on upper gastrointestinal pathology. Arch Intern Med. 152:1992;1289-1295.
13. MacDonald T.M., Morant S.V., Robinson G.C., Shield M.J., McGilchrist M.M., Murray F.E., McDevitt D.G. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 315:1997;1333-1337.
14. Steffensen F.H., McLaughlin J.K., Olsen J.H. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 95:2000;2218-2224.
15. Hernandez-Diaz S., Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Intern Med. 160:2000;2093-2099.
16. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
17. Wallace J.L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Clin Gastroenterol. 5:2001;691-703.
18. Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketarolac, other non-steroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 158:1998;33-39.
19. Pahor M., Guralnik J.M., Furberg C.D., Carbonin P., Havlik R.J. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 347:1996;1061-1065.
20. Pahor M., Carosella L., Pedone C., Manto A., Carbonin P. Trends of the characteristics and appropriateness of admissions to acute geriatric and medical wards in Italy from 1988 through 1993. Gruppo Italiano di Farmacovigilanza nell'Anziano-GIFA. Eur J Epidemiol. 12:1996;563-571.
21. Carosella L., Pahor M., Pedone C., Zuccala G., Manto A., Carbonin P. Pharmacosurveillance in hospitalized patients in Italy. Study design of the "Gruppo Italiano di Farmacovigilanza nell'Anziano" (GIFA). Pharmacol Res. 40:1999;287-295.
22. Passaro A., Volpato S., Romagnoni F., Manzoli N., Zuliani G., Fellin R. Benzodiazepines with different half-life and falling in a hospitalized population: The GIFA study: Gruppo Italiano di Farmacovigilanza nell'Anziano. J Clin Epidemiol. 53:2000;1222-1229.
23. Zuccala G., Pedone C., Cocchi A., et al. Older age and in-hospital development of hypokalemia from loop diuretics: results from a multicenter survey. GIFA Investigators. Multicenter Italian Pharmacoepidemiologic Study Group. J Gerontol A Biol Sci Med Sci. 55:2000;M232-M238.
24. Zuccala G., Pedone C., Cocchi A., et al. Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study. Gruppo Italiano di Farmacoepidemiologia nell'Anziano (GIFA) investigators. Clin Pharmacol Ther. 67:2000;314-322.
25. Landi F., Onder G., Gambassi G., Pedone C., Carbonin P., Bernabei R. Body mass index and mortality among hospitalized patients. Arch Intern Med. 160:2000;2641-2644.
26. Zuccala G., Onder G., Pedone C., et al. Cognitive dysfunction as a major determinant of disability in patients with heart failure: results from a multicentre survey. On behalf of the GIFA SIGG-ONLUS) Investigators. J Neurol Neurosurg Psychiatry. 70:2001;109-112.
27. Onder G., Gambassi G., Landi F., et al. Trends in antihypertensive drugs in the elderly: the decline of thiazides. J Hum Hypertens. 15:(5):2001;291-297.
28. Volpato S., Zuliani G., Guralnik J.M., Palmieri E., Fellin R. The inverse association between age and cholesterol level among older patients: the role of poor health status. Gerontology. 47:2001;36-45.
29. Gutthann S.P., Garcia Rodriguez L.A., Raiford D.S. Individual nonsteroidal inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 8:1997;18-24.
30. Garcia Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
31. Weill J., Langman M.J., Wainwright P. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatiry drugs. Gut. 46:2000;27-31.
32. Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:1987;373-383.
33. Deyo R.A., Cherkin D.C., Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45:1992;613-619.
34. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsterodal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Eng J Med. 343:2000;834-839.
35. Kaplan R.C., Heckbert S.R., Koepsell T.D., et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc. 49:2001;126-133.
36. Weil J., Colin-Jones D., Langman M., Lawson D., Logan R., Murphy M., Rawlins M., Vessey M., Wainwright P. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 310:1995;827-830.
37. Hernández-Díaz S., García-Rodriguez A.G. Incidence of serious upper gastrointestinal bleeding (perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 55:2002;157-163.
38. Roth S.H., Bennet R.E. NSAIDs, peptic ulcer, esophageal disease, and gastropathy. Famey J.P., Paulus H.E. Therapeutic application of NSAIDs. Subpopulations and new formulations. 1992;Marcel Dekker, New York.
39. Willett L.R., Carson J.L., Strom B.L. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Saf. 10:1994;170-181.
40. Griffin M.R., Piper J.M., Daugherty J.R., Snowden M., Ray W.A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 114:1991;257-263.
41. Langman M.J., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
42. Lanza L.L., Walker A.M., Bortnichak E.A., Dreyer N.A. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med. 155:1995;1371-1377.
43. Henry D., Lim L.L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 312:1996;1563-1566.
44. Ivey R.J., Silvoso G.R., Krause W.J. Effect of paracetamol on gastric mucosa. BMJ. 1:1978;1586-1588.
45. Graham D.Y., Smith J.L. Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa in normal subjects. A double-blind endoscopic study. Gastroenterology. 88:1985;1922-1925.
46. Johnsen S.P., Sorensen H.T., Mellemkjoer L., et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost. 86:2001;563-568.
47. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 348:1996;423-428.
48. Vreeburg E.M., de Bruijne H.W., Snel P., Bartelsman J.W., Rauws E.A., Tytgat G.N. Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers. Eur J Gastroenterol Hepatol. 9:1997;41-44.
49. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Saf. 11:1994;163-178.
50. Voutilainen M., Sokka T., Juhola M., et al. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationship to gastric histology, Helicobacter pylori infection and other risk factors for peptic ulcer. Scand J Gastroenterol. 33:1998;811-816.
51. Perretti M., Mugridge K.G., Wallace J.L., Parente L. Reduction of aspirin-induced gastric damage in rats by interleukin-1 beta: possible involvement of endogenous corticosteroids. J Pharmacol Exp Ther. 261:1992;1238-1247.
52. ® system. vol. 109:2001;MICROMEDEX, Inc. Greenwood Village, CO.
53. Legault C., Furberg C.D., Wagenknecht L.E., et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke. 27:1996;593-598.
54. Maringhini A., Simonetti R.M., Marceno M.P., Pagliaro L. Propranolol for gastrointestinal bleeding in cirrhosis. N Engl J Med. 307:1982;1710.
55. Lebrec D., Bernuau J., Rueff B., Benhamou J.P. Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis. N Engl J Med. 307:1982;560.
56. Alabaster S.L., Gogel H.K., McCarthy D.M. Propranolol withdrawal and variceal hemorrhage. JAMA. 250:1983;3047.
57. Jick H., Porter J. Drug induced gastrointestinal bleeding. Report for the Boston Collaborative Drug Surveillance Program, Boston, University Medical Center. Lancet. 2:1978;87-89.